Know Cancer

or
forgot password

Intensive Combination Chemotherapy With Autologous Bone Marrow Rescue for Metastatic Breast Cancer After Intitial Cytoreduction With Standard Agents: A Phase II Study


Phase 2
18 Years
55 Years
Not Enrolling
Female
Metastatic Breast Cancer

Thank you

Trial Information

Intensive Combination Chemotherapy With Autologous Bone Marrow Rescue for Metastatic Breast Cancer After Intitial Cytoreduction With Standard Agents: A Phase II Study


Inclusion Criteria:



- breast carcinoma at first clinical evidence of metastatic disease

- must have measurable disease by physical exam, x-ray, or scan

- Age < or equal to 55

- performance status 0-2

Exclusion Criteria:

- can't have had more than one prior chemotherapy regimen

- can't have had concurrent hormonal therapy

- no brain metastases

- no previous pelvic radiation

- no history of another malignancy

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Quality of maximal response; time to initial disease progression; and overall survival

Outcome Time Frame:

undetermined

Safety Issue:

No

Principal Investigator

George Selby, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Oklahoma

Authority:

United States: Institutional Review Board

Study ID:

OU 8701

NCT ID:

NCT00584766

Start Date:

October 1987

Completion Date:

May 2002

Related Keywords:

  • Metastatic Breast Cancer
  • Breast Neoplasms

Name

Location

University of Oklahoma Health Sciences CenterOklahoma City, Oklahoma  73104